The Pershing Square Sohn Cancer Research Alliance has announced the recipients of the 2018 Pershing Square Sohn Prize for Young Investigators in Cancer Research.
Established in 2013 as part of a $25 million partnership between the Pershing Square and Sohn Conference foundations, the annual prize is designed to provide early-stage funding for promising young cancer research scientists in the New York City area. This year's seven winners will each receive $200,000 per year for up to three years to enable them to pursue bold research at a stage when traditional funding often is lacking.
This year's recipients are Daniel Bachovchin (Memorial Sloan Kettering Cancer Center), who is working to develop a highly innovative chemical-proteomics platform that can determine the mechanism of action of anti-cancer protease inhibitors; Kivanc Birsoy (Rockefeller University), who aims to identify the nutritional requirements cancer cells need to metastasize to different organs; Alberto Ciccia (Columbia University Medical Center), who is pursuing new therapies for BRCA1-mutant tumors; Camila dos Santos (Cold Spring Harbor Laboratory), whose goal is to devise new strategies for reducing breast cancer occurrence; Benjamin Greenbaum (Icahn School of Medicine at Mount Sinai), who uses math and physics to analyze highly complex data and better understand responses to immunotherapy; Dan Landau (Weill Cornell Medicine and New York Genome Center), whose research is focused on precision customization of anti-cancer therapy to prevent tumor evolution to treatment resistance; and Benjamin Martin (Stony Brook University School of Medicine), who is working to develop a better understanding of the metastasis from primary tumor to new sites in the body.
"I'm incredibly proud of the thirty-two early-career researchers who have received the prize since we started it five years ago," said Bill Ackman, co-founder of the Pershing Square Foundation and CEO of Pershing Square Capital Management. "These innovative scientists bring the creativity and passion needed to think unconventionally and explore uncharted territory as they work to discover cures for cancer."